A detailed history of Flaharty Asset Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Flaharty Asset Management, LLC holds 32,000 shares of RVNC stock, worth $82,240. This represents 0.02% of its overall portfolio holdings.

Number of Shares
32,000
Holding current value
$82,240
% of portfolio
0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$4.65 - $9.31 $148,800 - $297,920
32,000 New
32,000 $157,000
Q1 2023

May 10, 2023

SELL
$18.36 - $35.27 $119,340 - $229,255
-6,500 Reduced 48.32%
6,952 $223,000
Q4 2022

Feb 14, 2023

BUY
$18.32 - $30.66 $18,320 - $30,660
1,000 Added 8.03%
13,452 $248,000
Q3 2022

Nov 02, 2022

SELL
$14.33 - $28.47 $71,650 - $142,350
-5,000 Reduced 28.65%
12,452 $336,000
Q2 2022

Jul 11, 2022

BUY
$11.52 - $20.4 $23,040 - $40,800
2,000 Added 12.94%
17,452 $241,000
Q4 2021

Feb 15, 2022

BUY
$12.46 - $27.87 $192,531 - $430,647
15,452 New
15,452 $252,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Flaharty Asset Management, LLC Portfolio

Follow Flaharty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Flaharty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Flaharty Asset Management, LLC with notifications on news.